Drug Development in Non-Muscle-Invasive Bladder Cancer (NMIBC) from Scientific, Regulatory, Clinician, and Patient Perspectives 2021 Annual Meeting

Viewing 1-15 of 15 articles

The Role of Radiology and Radiomics in Staging and Risk Stratification of Non-Muscle Invasive Bladder Cancer

Predicting Response to BCG

Special Considerations for Upper Tract Urothelial Carcinoma and Lynch Syndrome

Can We Identify Patients Who Should Undergo Immediate Cystectomy?

Novel and Multimodality Management Strategies for Localized Upper Tract Urothelial Carcinoma

Perioperative Chemotherapy and Targeted Therapy for Locally Advanced UTUC

Genomics of Upper Tract Urothelial Carcinoma

The Science of Combination Therapy in Non-Muscle-Invasive Bladder Cancer (NMIBC)

The Natural History of High-Risk NMIBC: Novel Therapies Versus Cystectomy

Sequential Therapy in BCG Unresponsive Disease

Keynote: Racial Disparities in Bladder Cancer Clinical Trials

Trial Design Considerations for Intermediate Risk Non Muscle-Invasive Bladder Cancer

What Novel Therapies Can Compete (or Combine) with BCG in BCG-naïve Non-Muscle Invasive Bladder Cancer (NMIBC)?

Model Systems to Facilitate Development of Therapies for Non-Muscle-Invasive Bladder Cancer

Regulatory Considerations in the BCG-Naïve Non-Muscle-Invasive Bladder Cancer Setting

email news signup